NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?

NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?

Until very recently, hidradenitis suppurativa (HS) was largely ignored by medical regulators, the pharmaceutical industry and society in general. There were no formal HS guidelines, no licensed interventions for HS and no National Institute for Health and Care Excellence (NICE)-approved treatments. In the U.K., Individual Patient Funding Requests to access biologic therapy for HS created delays and some requests were declined. Patients at the end of the financial year were potentially disadvantaged and access varied from region to region; the ad hoc model of funding was not a sustainable solution.


Access full article